


SENIOR MANAGEMENT BIOS



LEONARD S. SCHLEIFER, MD, PhD

Founder, President & Chief Executive Officer


Leonard S. Schleifer, MD, PhD, founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regeneron's founding scientist, Dr. Yancopoulos, built and has managed the Company over the past nearly 30 years. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology.



GEORGE D. YANCOPOULOS, MD, PhD

Founding Scientist, President, Regeneron Laboratories & Chief Scientific Officer

George D. Yancopoulos, MD, PhD, joined Dr. Schleifer in 1989 as founding scientist of the Company, and together they built and have managed the Company since then. Dr. Yancopoulos is currently President and Chief Scientific Officer, and has served on the board since 2001. He received his MD and PhD from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the six FDA-approved drugs the Company has developed, KEVZARA[®], DUPIXENT[®], PRALUENT[®], EYLEA[®], ZALTRAP[®], and ARCALYST[®], as well as of its foundation technologies, including the TRAP technology, VelociGene[®] and VelocImmune[®].



MICHAEL ABERMAN, MD

Senior Vice President, Strategy & Investor Relations

Michael Aberman, MD, has been Senior Vice President, Strategy and Investor Relations since January 2015. From March 2010 to December 2014, he served as Vice President, Strategy and Investor Relations. Prior to joining the Company, he spent six years as a Wall Street analyst covering the biotechnology industry. From March 2006 until joining the Company, he was Director and Senior Biotechnology Analyst at Credit Suisse. Prior to that, from March 2004 to March 2006, he worked as a Biotechnology Analyst at Morgan Stanley, Inc. From February 2002 to March 2004, Dr. Aberman was Director of Business Development at Antigenics Inc., an oncology-focused biotechnology company. Dr. Aberman received his MD with honors from the University of Toronto and his MBA from the Wharton School of the University of Pennsylvania.



NED BRAUNSTEIN, MD

Senior Vice President, Regulatory Affairs & Pharmacovigilance

Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs & Pharmacovigilance. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.



THOMAS DALY, PhD

Senior Vice President, Preclinical Development & Protein Chemistry


Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in Biochemistry from Rice University and his BS in biochemistry from Hofstra University.



JAMES P. FANDL, PhD

Senior Vice President, Protein Expression Sciences


James P. Fandl, PhD, joined Regeneron in 1989 as Scientist in the Protein Expression Group. During his tenure at Regeneron, Dr. Fandl has held numerous positions; he was appointed Vice President of Protein Expression Sciences in 2001 and Senior Vice President of Protein Expression Sciences in 2015. His research group developed the VelociMab® suite of proprietary technologies, including EESYR®, FASTR™, NICE® and BST, which enabled Dr. Fandl to demonstrate his knack for acronyms. He received his AB in Biology from Franklin & Marshall College and his PhD in Microbiology from the University of California, Davis.



ROBERT E. LANDRY

Senior Vice President, Finance & Chief Financial Officer

Robert E. Landry has been Senior Vice President, Finance since September 2013 and Chief Financial Officer since October 2013. Previously, Mr. Landry served as Senior Vice President, Treasurer, at Pfizer Inc. from October 2012 to August 2013 and Senior Vice President – Finance, Pfizer's Diversified Business, from October 2009 to October 2012. Prior to those roles, Mr. Landry held a number of positions at Wyeth, which was acquired by Pfizer Inc. in October 2009, including Treasurer and Principal Corporate Officer from 2007 to 2009, Director of Pharmaceutical Marketing and Sales of Wyeth's Australian affiliate from 2006 to 2007, and Chief Financial Officer of Wyeth's Australian and New Zealand affiliates from 2004 to 2006.



JOSEPH J. LAROSA

Senior Vice President, General Counsel & Secretary


Joseph J. LaRosa has been Senior Vice President, General Counsel, and Secretary since September 2011. Before joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel, and Secretary at Nycomed US Inc. Mr. LaRosa's prior experience includes working in a number of senior legal positions at Schering-Plough Corporation from 1993 to 2009, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD from New York University School of Law.



BETH F. LEVINE

Senior Vice President, Associate General Counsel, Chief Compliance Officer

Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Ms. Levine spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Levine was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Levine received a BS from Cornell University and a JD from Fordham Law School.



JAY S. MARKOWITZ, MD

Senior Vice President, Portfolio Management

Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.



ANDREW (DREW) MURPHY, PhD

Senior Vice President, Research of Regeneron Laboratories

Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery, Bioinformatics group and the Target Discovery group, and is now the Senior Vice President of Research, Regeneron Laboratories. Dr. Murphy is a co-inventor of several of Regeneron's key technologies — VelociGene® and VelocImmune® — and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.



SALLY A. PAULL

Senior Vice President, Human Resources

Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BA from the United States Air Force Academy and an MA in International Relations (MAIR) from the University of Delaware.



PETER POWCHIK, MD

Senior Vice President, Clinical Development

Peter Powchik, MD, has been Senior Vice President, Clinical Development since joining the Company in October 2006. Prior to joining the Company, Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his MD from New York University School of Medicine.



NICHOLAS PAPADOPOULOS, PhD

Senior Vice President, Research & Development Operations

Nicholas Papadopoulos, PhD, joined Regeneron in 1996 as a Scientist in the Protein Sciences Department. In 2007, Dr. Papadopoulos was named Senior Director of Therapeutic Proteins, with responsibilities dedicated to overseeing the generation of fully human VelocImmune® antibodies. He was named Vice President in 2009 and Senior Vice President in January 2015. In 2016, Dr. Papadopoulos transitioned to a new role as Senior Vice President, Research & Development Operations. He received his BS in Chemistry from the State University of New York and his PhD in Chemistry from The Pennsylvania State University. Dr. Papadopoulos completed his postdoctoral training in the department of Microbiology and Immunology at the Albert Einstein College of Medicine.



NEIL STAHL, PhD

Executive Vice President, Research & Development

Neil Stahl, PhD, has been Executive Vice President, Research and Development since January 2015. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. He joined the Company in 1991. Dr. Stahl received his PhD in Biochemistry from Brandeis University.



ROBERT J. TERIFAY

Executive Vice President, Commercial

Robert J. Terifay has been Executive Vice President, Commercial since January 2016. From February 2007 to December 2015, he served as Senior Vice President, Commercial. Prior to joining the Company, Mr. Terifay was employed at several biopharmaceutical companies. From January to October 2006, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals. Prior to his employment at Arginox, Mr. Terifay was Senior Vice President, Business Operations at Synta Pharmaceuticals from March to December 2005. From February 2002 until March 2005, he held various senior commercial and marketing positions at Millennium Pharmaceuticals, Inc., most recently as Senior Vice President, Oncology Commercial. Mr. Terifay was Vice President, Marketing at Cor Therapeutics, Inc. from 1996 until its acquisition by Millennium Pharmaceuticals, Inc. in February 2002. Mr. Terifay was Executive Vice President of Strategic Services at Saatchi & Saatchi, an advertising firm, from 1993 to 1996. From 1985 to 1993, he held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received his Master of Management degree in Marketing and Health Service Management from the Kellogg School of Management at Northwestern University.



DANIEL VAN PLEW

Executive Vice President & General Manager, Industrial Operations & Product Supply

Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From April 2008 to December 2015, Mr. Van Plew served as Senior Vice President and General Manager, Industrial Operations and Product Supply. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in 2007. From 2006 until 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from The Pennsylvania State University and his MBA from Michigan State University.



DAVID WEINREICH, MD, MBA

Senior Vice President, Global Clinical Development

David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. In 2017 he became the Senior Vice President, Global Clinical Development. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.